George D. Yancopoulos (born 1959) is a Greek-American biomedical scientist who is the co-founder, president and chief scientific officer of Regeneron Pharmaceuticals.

He then worked in the field of molecular immunology at Columbia University with Dr. Fred Alt, for which he received the Lucille P. Markey Scholar Award.

They went on to show that MuSK is required for the formation of the neuromuscular junction, the key structure which allows motor neurons to induce skeletal muscle to contract.

[13] They next demonstrated that the ligand for MuSK is agrin, a protein secreted by the motor neuron to induce formation of the neuromuscular junction.

[19] More recently, Yancopolous and his colleagues developed a cocktail of antibodies, using the mouse with a human immune system, to block the SARS-CoV-2 virus in order to treat COVID-19.

[27] In 2016, Leonard Schleifer and George Yancopoulos were named the Ernst & Young Entrepreneurs of the Year 2016 National Award Winners in life sciences.

[29] He was inducted into the Bronx Science Hall of Fame in 2017 and was recognized by the Yale School of Management, CEO Institute as a Legends in Leadership Award in 2017.

[30][31] In 2019, he received the Alexander Hamilton Award,[32] Columbia's highest honor for contributions to science and medicine, and was recognized by Forbes as one of America's 100 Most Innovative Leaders.

However, as is typical for experimental drugs, the FDA "expanded access" regulation, technically known as 21 CFR 312.310, allowed Trump's physicians to request "compassionate use" of REGN-COV.

[46] The successful track record of VelocImmune technology at producing safe and effective monoclonal antibody treatments against viruses presumably contributed to the FDA's decision to grant compassionate use to Donald Trump.